Kendra Wilson, DO
Hospitalist · Tulsa, OKNPI 1104448083
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $615 of the $950 with a category attached, or 64.7%. 12 manufacturers reported payments, led by AstraZeneca at 46.7% of the total. 2025 is the largest year on record at $672, 5.9 times the $113 reported in 2022. Among hospitalist clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 28 payments — averaging $33.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$444
- Tempus AI, Inc$155
- AbbVie$108
- Seagen Inc.$75
- Blueprint Medicines Corporation$33
- Eisai Inc.$28
- plus $109 from 6 others
What the payments were for
- Food & beverage$61565%
- Education$33535%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 10 | $444 |
| Tempus AI, Inc | 7 | $155 |
| AbbVie | 2 | $108 |
| Seagen Inc. | 1 | $75 |
| Blueprint Medicines Corporation | 1 | $33 |
| Eisai Inc. | 1 | $28 |
| Pfizer | 1 | $24 |
| Incyte Corporation | 1 | $20 |
| Pharmacosmos Therapeutics Inc. | 1 | $18 |
| Karyopharm Therapeutics Inc. | 1 | $18 |
| Blue Earth Diagnostics | 1 | $14 |
| ADC Therapeutics America, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LOKELMA$113
How this compares
$950 in reported general payments places this provider in the 90th percentile of 234 hospitalist providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Furosemide | 19 | $94 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 13 | $82 |
| Prednisone | 17 | $62 |
| Pantoprazole Sodium | 12 | $58 |
Paid to pharmacies, not to this prescriber.
Other hospitalist in Tulsa
- Kishen PatelTulsa$4K
- Mark ThngTulsa$4K
- Jawad BabarTulsa$2K
- Bhavik PatelTulsa$2K
- Nishant PaudelTulsa$1K
- Ziad SousTulsa$1K
- Caleb SevernsTulsa$1K
- Dustin FravelTulsa$980
- Sudha NiraulaTulsa$936
- Sanjana MullangiTulsa$783
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.